Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1CNS 1Breast 1

Conditions

Glioblastoma 472Brain Neoplasms 306Glioma 257Neoplasms 122Astrocytoma 88Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 70Neuroblastoma 65Central Nervous System Neoplasms 61Melanoma 58Recurrence 46Lung Neoplasms 45Pancreatic Neoplasms 41Oligodendroglioma 37Ovarian Neoplasms 36Colorectal Neoplasms 36Neoplasm Metastasis 33Sarcoma 32Medulloblastoma 28Stomach Neoplasms 27Gliosarcoma 27Lymphoma 25Prostatic Neoplasms 24Head and Neck Neoplasms 24Neurofibromatosis 1 23Rhabdomyosarcoma 21Neurofibroma, Plexiform 19Esophageal Neoplasms 19Diffuse Intrinsic Pontine Glioma 19Cholangiocarcinoma 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anophthalmia with pulmonary hypoplasia × CNS × Clear all
NCT06458712 2026-05-27

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Duke Street Bio Ltd

Phase 1 Recruiting
180 enrolled
CNS

Kenny-Caffey syndrome, Type 1, Anophthalmia with pulmonary hypoplasia, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡